Search Medical Condition
Please enter condition
Please choose location

Oslo, Norway Clinical Trials

A listing of Oslo, Norway clinical trials actively recruiting patients volunteers.

RESULTS

Found (304) clinical trials

Phase 1 Trial of MSC2490484A an Inhibitor of a DNA-dependent Protein Kinase in Combination With Radiotherapy

MSC2490484A or M3814 is an investigational drug that is being evaluated for the treatment of subjects with locally advanced tumors. The main purposes of this study are to determine the safety, the tolerability and the efficacy of MSC2490484A in combination with radiotherapy and in combination with chemoradiotherapy (Radiotherapy + cisplatin).

Phase

0.0 miles

Learn More »

OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients

This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOX) for the treatment of urinary incontinence due to overactive bladder in pediatric patients between the ages of 12 to 17 years who have not been adequately managed with anticholinergics.

Phase

0.0 miles

Learn More »

Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients

To characterize the pharmacokinetics (PK) of naloxegol after single oral dose and through population PK in paediatric patients with opioid induced constipation (OIC).

Phase

0.0 miles

Learn More »

CENTER-TBI: Collaborative European NeuroTrauma Effectiveness Research in TBI

Introduction CENTER-TBI (Collaborative European NeuroTrauma Effectiveness Research in TBI) (www.center-tbi.eu) is a project embedded within the International Initiative on TBI Research (InTBIR) (http://intbir.nih.gov/), as a collaboration between the European Commission (EC), the US National Institute of Neurological Disorders and Stroke (NIH-NINDS) and the Canadian Institute of Health Research (CIHR). Research ...

Phase N/A

0.0 miles

Learn More »

Modufolin in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer

The study will investigate the tolerability of Modufolin at four (4) dose levels (30, 60, 120 and 240 mg/m2) in two (2) treatment combinations of the chemotherapeutic agents 5-FU and Oxaliplatin during eight (8) weeks of treatment. The tolerability of the two (2) lower doses of Modufolin (30 and 60 ...

Phase

0.0 miles

Learn More »

The objective of this study is to assess efficacy and safety of radium 223 dichloride in subjects with human epidermal growth factor receptor 2 (HER2) negative hormone receptor positive breast cancer with bone metastases treated with exemestane and everolimus.

Phase

0.0 miles

Learn More »

NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating and Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall

Patients who will be allocated in arm A, will receive a single intratumor injection of NBTXR3 and will receive external beam radiotherapy starting 24hrs after the injection up to completion of 5 weeks, 5 days a week of treatment (50Gy, 2Gy/fraction). Then, all patients will undergo surgical resection of the ...

Phase

0.0 miles

Learn More »

Trial Assessing Efficacy Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders

A study to evaluate the effect of 24 weeks of subcutaneous (SC) evolocumab compared with placebo,when added to standard of care, on percent change from baseline in lowdensity lipoprotein cholesterol (LDL-C) in pediatric subjects 10 to 17 years of age with HeFH

Phase

0.0 miles

Learn More »

DC Vaccination for Post-remission Therapy in AML

This is a multi-centre, open label, prospective, non-randomized phase I/II trial in 20 patients including a safety-run in phase I part comprising 6 patients. Trial subjects will receive repeated immunotherapies with autologous Dendritic Cells (DCs), presenting two leukemia-associated antigens.

Phase

0.0 miles

Learn More »

Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL

This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of CTL019 in pediatric patients with r/r B-cell ALL. The study will have the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation & Lymphodepleting Chemotherapy), Treatment and Primary Follow-up, Secondary Follow-up (if applicable) and ...

Phase

0.0 miles

Learn More »